Martin K. (Casey) Childers, DO, PhD
Gene therapy for myotubular myopathy, a congenital muscle disease, that causes severe and fatal weakness of the breathing muscles is a focus of the Childers lab. Our group is leading the development of this new gene therapy technology to translate findings in animals to treat human patients. The Childers lab also uses a technique to “reprogram” small samples of patient blood or urine into pluripotent stem cells that can be tested in a petri dish without harm to the patient. Using these powerful techniques our hope is to find and develop new therapy for inherited muscle diseases.